Trend Of Outsourcing Trials to China, India Raises New Ethics Questions
This article was originally published in PharmAsia News
The trend by multinational pharmaceutical companies conducting clinical trials in China, India and other nations with emerging economies may be upsetting accepted ethics of trials. Viral Genetics, a U.S. biotech, came under criticism when it conducted a trial of an AIDS drug in China by giving a control group a placebo instead of antiretrovirals, the accepted trial behavior in the Western World. Chinese authorities investigated after several AIDS patients died during the trial, and concluded "no serious violation of ethical principles." That incident highlights increasing concerns over quality, research ethics and lives of patients in outsourced trials. (Click here for more - may require a subscription
You may also be interested in...
Announcing his “first step to take on pricing of generic drugs,” billionaire Mark Cuban recently associated his name with a new US generics company “to show that capitalism can be compassionate.” In an exclusive chat with Generics Bulletin, the newly established company’s CEO Alex Oshmyansky revealed that they started working on the company “in stealth” since 2018.
GSK is transferring technology to make its malaria vaccine antigen to Bharat Biotech and by 2029 will also transfer rights to supply the vaccine to WHO-approved immunization programs. The deal is expected to improve access via lower cost of the vaccine for such programs
Rules covering OTC medical devices, herbals and online activities have been added for the first time to the Irish Pharmaceutical Healthcare Association's Self-Care Advertising Code.